“…The authors claim priority over our case report, arguing for the previous publication of two studies where they used concurrent anti-PD1 therapy and stereotactic body radiotherapy (SBRT) in a heterogeneous series of head and neck cancers (HNC) from diverse sites, including sinonasal and nasopharyngeal cancers, among other more common subsites. However, they used an approach that differs in three fundamental aspects from that employed in our patient [1–3]. First, they used concurrent radiotherapy combined with anti-PD1 therapy, while in our patient IO (nivolumab) was administered before and after radiotherapy, but not ‘concurrently’ with radiotherapy.…”